Cost effectiveness analysis of a screening programme for asymptomatic Chlamydia trachomatis infections in a low prevalence female population (in US$)
| Net cost per woman cured | Net cost per MOA | |||
|---|---|---|---|---|
| Age group (years) | Direct only | Total | Direct only | Total |
| MOA = major outcome averted (either an episode of PID, chronic pelvic pain, ectopic pregnancy, tubal factor infertility, or neonatal pneumonia). | ||||
| 15–25 | 802 | 792 | 11 200 | 11 100 |
| 15–40 | 1220 | 1210 | 16 000 | 15 800 |